Latest News about UK:AZN
Recent news which mentions UK:AZN
   Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic
   
  
  
  December 04, 2023
  From MarketWatch
 
   AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
   
  November 09, 2023
  Tickers 
   AZN
  
  
  From MarketWatch
 
   Here’s what Ozempic, ASML and India’s fintech industry all have in common — and how one ETF takes advantage of all three
   
  
  
  October 17, 2023
  From MarketWatch
 
   Startup Cerebras stands out in the high-risk AI chip arena: ‘No one has built a chip this big’
   
  
  
  October 11, 2023
  From MarketWatch
 
   This fund shows that industry expertise can help you make a lot of money in the stock market
   
  
  
  October 02, 2023
  From MarketWatch
 
   JPMorgan says there may be many oil crises this decade as it lifts rating on energy stocks
   
  
  
  September 22, 2023
  From MarketWatch
 
   As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
   
  
  
  July 21, 2023
  From MarketWatch
 Tickers 
   AZN
  
  
  From MarketWatch
 
   AstraZeneca to decarbonize U.S. footprint by turning cow manure into renewable natural gas
   
  
  June 13, 2023
  From MarketWatch
 Tickers 
   AZN
  
  
  From MarketWatch
 From MarketWatch
 
   AstraZeneca says cancer drug Enhertu showed positive results
   
  March 06, 2023
  Tickers 
   AZN
  
  
  From MarketWatch
 
   FTSE 100 hits fresh record above 8,000 on weak pound and renewed demand for energy stocks
   
  
  
  February 16, 2023
  From MarketWatch
 Tickers 
   AZN
  
  
  From MarketWatch
 
   AstraZeneca says Forxiga approved in EU for heart failure
   
  February 07, 2023
  Tickers 
   AZN
  
  
  From MarketWatch
 
   Drug companies plan to raise prices on vital medicines to fund R&D, but they already spend more on shareholder returns
   
  
  
  January 13, 2023
  From MarketWatch
 
   Will 2023 be the year that pharma M&A makes a comeback?
   
  
  
  January 12, 2023
  From MarketWatch
 From MarketWatch
 
   Powell won’t stop rate hikes until he ‘terrifies’ the wealthiest of investors, says this CIO
   
  
  
  January 09, 2023
  From MarketWatch
 
   AstraZeneca will buy U.S.-based CinCor for cardiorenal asset
   
  
  
  January 09, 2023
  From MarketWatch
 
   AstraZeneca’s Forxiga gets EU approval recommendation for symptomatic chronic heart failure
   
  December 19, 2022
  Tickers 
   AZN
  
  
  From MarketWatch
 
   AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU
   
  December 19, 2022
  Tickers 
   AZN
  
  
  From MarketWatch
 
   Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen’s favorites for 2023
   
  
  
  December 10, 2022
  From MarketWatch
 
   AstraZeneca lifts guidance after forecast-beating profit and sales
   
  November 10, 2022
  Tickers 
   AZN
  
  
  From MarketWatch
 From MarketWatch
 
   AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints
   
  October 26, 2022
  Tickers 
   AZN
  
  
  From MarketWatch
 From MarketWatch
 
   Europe may give COVID vaccines full marketing authorization to avoid annual review, and WHO backs Gilead’s Veklury for severe disease
   
  
  
  September 16, 2022
  From MarketWatch
 
   AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
   
  
  
  September 14, 2022
  From MarketWatch
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
